Baidu
map

J Rheumatol:抗疟药可降低SLE患者感染的发生风险

2016-07-12 MedSci MedSci原创

据发表于Journal of Rheumatol的一项新的研究发现表明,抗疟药的使用可减少了系统性红斑狼疮患者严重感染的发生风险。“很多系统性红斑狼疮患者服用羟氯喹,使用这种药物发生并发症的风险较低,” Lisa J. Herrinton博士说道,“该研究更进一步证明了使用羟氯喹可能有益于降低感染的发生风险。”Herrinton及其同事使用来自Kaiser Permanente医疗保健计划的数据进

据发表于Journal of Rheumatol的一项新的研究发现表明,抗疟药的使用可减少了系统性红斑狼疮患者严重感染的发生风险。

“很多系统性红斑狼疮患者服用羟氯喹,使用这种药物发生并发症的风险较低,” Lisa J. Herrinton博士说道,“该研究更进一步证明了使用羟氯喹可能有益于降低感染的发生风险。”

Herrinton及其同事使用来自Kaiser Permanente医疗保健计划的数据进行一项新的研究,并确定了3030名系统性红斑狼疮(SLE)患者。研究人员对比了新使用糖皮质激素(GCS),抗疟药(AMS)或两者组合应用的SLE患者发生严重感染的风险。


结果表明,与开始使用AMs而未使用GCs的患者相比,使用 GCs治疗不超过15毫克/天的患者严重感染的发生风险比(HR)为3.9;而联合应用两种药物治疗的患者严重感染的发生的HR为零。

研究者将14名严重感染且使用GC不超过15毫克/天的患者分为两组(<7.5毫克/天, 7.5毫克/天≤X≤15毫克/天)。小于7.5毫克/天的患者严重感染的HR为4.6,7.5毫克/天≤X≤15毫克/天的患者严重感染的HR为3.1。

研究人员表示,开始使用大于15毫克/天GCS的患者感染的风险与联合使用GCs和AMs组合治疗的患者及仅使用GCs治疗的患者相似;虽然更多的研究表明GCs与AMS联合使用患者发生严重感染的风险较高。与普通人群相比,SLE患者发生严重感染的风险高6-7倍。

原始出处:

Monica Jaramillo. Antimalarials may reduce the risk of infection in patients with SLE. Healio, July 11, 2016.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
    2016-10-08 1e10c84am36(暂无匿称)

    文章很棒,继续学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
    2016-09-13 ylzr123

    赞一个!好文章拜读了,认真学习了。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1746454, encodeId=77ac1e46454a6, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Wed Dec 21 10:48:00 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951540, encodeId=06db1951540af, content=<a href='/topic/show?id=aeeb5545681' target=_blank style='color:#2F92EE;'>#抗疟药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55456, encryptionId=aeeb5545681, topicName=抗疟药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Aug 01 16:48:00 CST 2016, time=2016-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146046, encodeId=8843146046ae, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:34:58 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141762, encodeId=c975141e62b2, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:10 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125515, encodeId=cfde1255155e, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Sep 13 16:33:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344957, encodeId=6883134495e2d, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jul 14 08:48:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92970, encodeId=30bd929e0f6, content=这都可以,老药新用, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 13 16:34:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
    2016-07-13 oo902

    这都可以,老药新用

    0

相关资讯

首种合成生物抗疟药市场遇冷

2014年,法国巴黎制药巨头赛诺菲开始出售通过基因工程合成酵母制成的抗疟疾药物,此举被认为是合成生物学的一次巨大胜利。这种酵母在一个大桶中发酵,用于生产一种可转化成青蒿素的化学物质,使其用于有效的疟疾疗法——基于青蒿素的合成疗法(ACT)。很多人希望这一过程能够提供大量廉价药物,以应对这种每年在全球导致近50万人死亡的疾病。 然而,事实上赛诺菲在2015年根本未生产任何“半合成”青蒿素。该公司现

国家卫计委发布《抗疟药使用规范》解读

导  语: 国家卫计委提出到2015年,全国除云南部分边境地区外,其他地区均无本地感染疟疾病例;到2020年,全国消除疟疾。 一、标准出台的背景和意义 疟疾与艾滋病、结核一起,被世界卫生组织列为严重影响全球人民健康和生命安全的三大公共卫生问题。疟疾曾在我国广泛流行,发病率曾高居各种传染病之首。经过几十年积极有效的防治,我国疟疾发病率持续大幅度下降,并于201

用抗疟药治疗皮肤型红斑狼疮需要耐心

在美国皮肤病学会夏季学术会议上,宾夕法尼亚大学赫尔希医学中心皮肤病科的Jennie T. Clarke博士指出,要提高抗疟药对皮肤型红斑狼疮(CLE)的疗效还有很长的路要走,并且需要极大的耐心。抗疟药是治疗CLE的有效药物,但仍有约1/3的患者经这类药物治疗后无应答。超过半数的CLE患者经羟氯喹单药治疗后获得应答。 一项纳入128例CLE患者的研究显示,约55%的患者经羟氯喹单药治疗后获得应

Baidu
map
Baidu
map
Baidu
map